Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Fig. 2

Characterization of mPEG × CD20 BsAb a The gene constructs of BsAbs are composed of a signal peptide (SP), the anti-mPEG VL-Ck(L), the anti-mPEG VH-CH1(H), a flexible linker peptide and an anti-CD20 scFv (mPEG × CD20) or control anti-DNS scFv (mPEG × DNS). b The SDS-PAGE of purified mPEG × CD20 or mPEG × DNS under reducing and non-reducing conditions. M:pre-stained protein ladder. c The anti-mPEG and anti-CD20 functions of mPEG × CD20 and mPEG × DNS in CD20+ Raji cells were detected via sandwich cell-based ELISA (n = 3). Bars, SD

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us